Clinical Trials Logo

Hyperoxalemia clinical trials

View clinical trials related to Hyperoxalemia.

Filter by:
  • None
  • Page 1

NCT ID: NCT06225544 Not yet recruiting - Clinical trials for Cardiovascular Disease

Lumasiran in Hyperoxalaemic Patients on Haemodialysis

LHOxH
Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

This study will look at how well a drug that reduced the amount of oxalate in the body works in patients that have kidney disease and need dialysis treatment. People with kidney disease often have higher levels of oxalate in the blood. People with kidney disease are also at higher risk of having heart attacks, heart disease and strokes (these are called cardiovascular diseases). It is thought that high oxalate levels may increase the risk of these diseases. So we would like to study if this medicine can lower the amount of oxalate in the blood of dialysis patients and see if there is any change in the health of their heart. This medicine is already used for people who have high oxalate levels because of a genetic cause and has been used safely for patients on dialysis. The study will put the participants randomly into either the group getting the study medicine or the group getting a placebo (this will be a solution of saline water). Neither participants not the doctors will know whether the drug or placebo is given until after the end of the study. At the start of the study we will ask all the participants to have an echocardiogram (an ultrasound of the heart) and again 6 months later at the end of the study. We will also take blood tests once a month when the participants come for dialysis.

NCT ID: NCT04119765 Completed - Clinical trials for Short Bowel Syndrome

Plasma Oxalate in Patient With Short Bowel

OXAGO
Start date: February 27, 2020
Phase:
Study type: Observational

Hyperoxaluria due to fat malabsorption is seen in patients suffering from short bowel and can lead to stones and nephrocalcinosis. Not all patients are prone to these renal complications. only urinary oxaluria is measured in practice. Plasma oxalate shouldn't increase theoretically in these patients. However recent report showed an increase of plasma oxalate in patient with enteric hyperoxaluria. The aim of this study is to assess the plasma oxalate distribution in this specific population to have a new tool to predict renal complication of these patients.

NCT ID: NCT03391804 Completed - Clinical trials for Primary Hyperoxaluria

Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia

Start date: July 17, 2018
Phase: Phase 2
Study type: Interventional

Evaluate the efficacy and safety of ALLN-177 in reducing plasma and urinary oxalate levels in adult and pediatric patients with enteric hyperoxaluria and hyperoxalemia or primary hyperoxaluria